GRFS
Grifols, S.A.
NASDAQ · Healthcare · Drug Manufacturers - General · ES
$7.80
−1.02%Year over year
Reported trailing growth
- Revenue
- -0.2%
- EBITDA
- +15.5%
- EBIT
- -5.3%
- EPS
- +54.4%
- Free cash flow
- -11.4%
- Operating cash flow
- -0.9%
Forward estimates
Based on analyst estimates
- Revenue
- -3.4%
- EBITDA
- -41.9%
- EPS
- -4.9%
Three-year CAGR
- Revenue
- +6.0%
- EBITDA
- +10.8%
- EBIT
- +14.9%
- Net income
- +27.8%
- EPS
- +22.5%
- Free cash flow
- +41.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026